Aytu BioPharma

Aytu BioPharma(AYTU)

DENVER, CO
Diagnostics
WebsiteLinkedInCareers Page

Focus: Small Molecule, Diagnostics

Aytu BioPharma is a life sciences company focused on Small Molecule, Diagnostics.

GastroenterologyInfectious DiseasesOncology
Funding Stage
PUBLIC
Open Jobs
0

Products & Portfolio (2)

2 discontinued products not shown

KARBINAL ER
carbinoxamine maleate
Peak
ORAL · SUSPENSION, EXTENDED RELEASE
12.1 Mechanism of Action Carbinoxamine is an H1 receptor antagonist (antihistamine) that exhibits anticholinergic (drying) and sedative properties. Antihistamines compete with histamine for receptor sites on effector cells. 12.3 Pharmacokinetics Carbinoxamine Maleate extended-release oral suspension after single-dose administration of 16 mg was bioequivalent to the reference carbinoxamine immediate-release oral solution after the administration of two doses of 8 mg six hours apart under fasting conditions. The carbinoxamine mean (SD) peak plasma concentration (Cmax) was 28.7 (5.3) ng/mL at 6.7 hours after Carbinoxamine Maleate extended-release oral suspension administration. The plasma half-life of carbinoxamine was 17.0 hours. There was no effect of food on the pharmacokinetic parameters. Carbinoxamine Maleate extended-release oral suspension after multiple-dose administration of 16 mg every 12 hours for 8 days was bioequivalent to the reference carbinoxamine immediate-release oral solution after multiple-dose administration of 8 mg every 6 hours. The mean (SD) steady-state Cmax was 72.9 (24.4) ng/mL at 5.6 hours after Carbinoxamine Maleate extended-release oral suspension administration. Carbinoxamine mean (SD) minimum plasma concentration at steady-state was 51.8 (20.3) ng/mL.
2013
8
METADATE CD
methylphenidate hydrochloride
LOE Approaching
ORAL · CAPSULE, EXTENDED RELEASE
(CNS) stimulant. The mode of therapeutic action in ADHD is not known.
Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 15 years of age
2001
30

Pipeline & Clinical Trials

N/A
Clinical Trials (1)
NCT04758260Influence of the Antioxidant Treatment in the Oxidant-reduction Potential in Seminal Plasma in Men Whose Partners Will Undergo Through an Egg Donation Cycle
N/A
N/A
Clinical Trials (1)
NCT02839447A Clinical Evaluation of Semen Quality Using the MiOXSYS™ System 2.0
N/A
UVA Light Emitting Catheter
COVID-19 Pneumonia
N/A
Clinical Trials (1)
NCT05166915Respiratory COVID-19: A Randomized, Sham-Controlled Study
N/A
N/A
Clinical Trials (1)
NCT02786459Detection and Localization of Carcinoma Using High Resolution Transrectal Imaging - Proof of Concept Study
N/A
UV Light Treatment
Coronavirus
N/A
Clinical Trials (1)
NCT04572399UVA Light Device to Treat COVID-19
N/A
Phase 3
Clinical Trials (1)
NCT05463679Investigate Efficacy, Safety, and Pharmacokinetics of Enzastaurin for the Prevention of Arterial Events in Patients With Vascular Ehlers-Danlos Syndrome.
Phase 3
Phase 4
Clinical Trials (1)
NCT07169162ADZENYS XR-ODT™ in Children (4 to <6 Years) Diagnosed With Attention-deficit/Hyperactivity Disorder
Phase 4

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Portfolio: 4 approved products, 7 clinical trials
Top TAs: Gastroenterology
SEC Filings: 2 available
Portfolio Health
Peak3 (75%)
LOE Approaching1 (25%)
4 total products
Therapeutic Area Focus
Marketed
Pipeline

Financials (FY2025)

Revenue
$65M39%
R&D Spend
$3M(4%)32%
Net Income
-$16M
Cash
$20M
Source: SEC 10-K Filing